Is the key to curing the world’s most challenging diseases hidden in unlocking the power of fragmented biological data?

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Noema Pharma extends its series B funding to $147M, advancing phase 2 trials for CNS disorders like Tourette syndrome, ...

As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS program.

Novocure's PANOVA-3 trial shows TTFields therapy with chemotherapy improves survival in pancreatic cancer, marking a ...

Radiopharmaceuticals have also been the target of large partnership deals, including a recent $140 million partnership ...

Discover how a strategic acquisition in pharma packaging is set to drive growth as the market aims to double by 2028 ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

A conversation with Steve Rosenberg, CEO of uMotif electronic clinical outcome assessment (eCOA) - collecting data ...

The Portuguese contract development and manufacturing organization (CDMO) Hovione continues its spray drying expansion with ...